Format

Send to

Choose Destination
Int J Public Health. 2016 Sep;61(7):847-60. doi: 10.1007/s00038-016-0842-8. Epub 2016 Aug 4.

Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review.

Author information

1
Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany. oliver.damm@uni-bielefeld.de.
2
Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany.
3
GlaxoSmithKline Germany, Prinzregentenplatz 9, 81675, Munich, Germany.
4
Xcenda GmbH, Lange Laube 31, 30159, Hanover, Germany.

Abstract

OBJECTIVES:

Despite the availability of vaccines and the existence of public vaccination recommendations, outbreaks of vaccine-preventable childhood diseases still cause public health debate. The objective of this systematic review was to provide an overview of the current epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany.

METHODS:

We systematically reviewed studies published since 2000. The literature search was conducted using PubMed and EMBASE. Also, we used German notification data to give an up-to-date overview of the epidemiology of the four diseases under consideration.

RESULTS:

Thirty-six studies were included in our review. Results suggest that there is still considerable morbidity due to childhood diseases in Germany. Studies providing cost estimates are scarce. Comparative analyses of different data sources (notification data vs. claims data) revealed a potential underestimation of incidence estimates when using notification data. Furthermore, several studies showed regional differences in incidence of some of the diseases under consideration.

CONCLUSIONS:

Our findings underline the need for improved vaccination and communication strategies targeting all susceptible age and risk groups on a national and local level.

KEYWORDS:

Childhood diseases; Economic burden; Epidemiology; Germany

PMID:
27488917
PMCID:
PMC5002040
DOI:
10.1007/s00038-016-0842-8
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

OD worked on Projects funded by the GSK group of companies, Sanofi Pasteur MSD and AstraZeneca Germany. JW worked on Projects funded by the GSK group of companies and Sanofi Pasteur MSD. CP and SB worked on Projects funded by the GSK group of companies. SW is employed by the GSK group of companies and reports personal fees from GlaxoSmithKline Biologicals SA. RW is employed by the GSK group of companies and reports shares. WG declares that he has no conflict of interest. Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors. Funding This systematic review was fully funded by GlaxoSmithKline Biologicals SA, which also funded costs associated with the development and the publishing of the present manuscript.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center